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Purpose: To study phenotype-genotype correlation in patients who have retinoma, which is a benign tumor resembling
the post irradiation regression pattern of retinoblastoma (RB).
Methods: We selected patients who had retinoma and positive family history for RB and patients who had retinoma in
one eye and either retinoma or RB in the other eye. The study included 22 patients with available DNA: 18 from 11
families and four sporadic cases. DNA was extracted from peripheral blood leukocytes. The RB1 gene was screened by
DHPLC and direct sequencing of the promoter and all the exons.
Results: We identified 17 occurrences of 11 distinct germline mutations in two sporadic and in 15 familial cases (nine
families). The 11 identified mutations were located in exons 1, 10,11,13,14, and 19 to 23. Four of the identified mutations
were not previously reported, including g.64407delT, g.153236A>T, g.156743delTCTG, and g.162078delA. Eight out
the 11 mutations were truncating and three were nontruncating (missense). There was no correlation between the type of
mutation and the number of tumor foci per eye (RB or retinomas). Highly heterogeneous intrafamilial expressivity was
observed.
Conclusions: To our knowledge, this study is the largest series of mutations of consecutive retinoma patients. The present
data suggest that the type of inherited mutations underlying retinoma is undistinguishable from RB related ones, i.e.,
largely dominated by truncating mutants. This finding is in contrast with the RB1 genotypic spectrum of mutations
associated with low-penetrance RB, i.e., nontruncating mutants. The molecular mechanism underlying low-penetrance
and attenuated expressivity (retinomas) appeared to be distinct.
Mutations of the RB1 gene can result in either malignant
retinoblastoma (RB; OMIM 180200) or benign retinoma [1].
Retinoma mimics the postirradiation regression pattern of RB
[1-4]. On histology, necrosis and mitoses are absent in contrast
with RB [5]. According to Knudson’s observation, both
alleles of the RB1 gene must be inactivated to develop a tumor
[6]. Hereditary germline mutations account for 40% of cases
and nonhereditary somatic mutations for the remaining 60%
[7]. For hereditary cases, mode of inheritance is autosomal
dominant; 90% of germline-mutation carriers develop RB or
retinoma (high penetrance) with most of them presenting
multiple tumors in both eyes (high expressivity).
Nevertheless, low penetrance is observed when germline
mutation carriers do not develop RB and reduced expressivity
when only unilateral RB or retinoma occurs [8,9]. To better
describe low-penetrance RB families with regard to both
penetrance and expressivity, Lohmann et al. [9] introduced
the disease-eye ratio (DER), which is the ratio of the number
of eyes containing tumors to the number of mutation carriers
in a family. Typically, diseased-eye ratios are less than 1.0 in
low-penetrance families and 1.5 or greater in full-penetrance
families [9].
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In 70% of RB cases loss of the wild-type allele, or loss of
heterozygosity happens through mitotic recombination or
nondisjunction with or without concomitant duplication of the
mutated chromosome [10]. If the predisposing mutation is
truncating, one could expect that loss of heterozygosity would
lead to complete loss of functional protein and thus to RB with
high penetrance and expressivity [8,9,11,12]. In contrast, the
molecular basis of low-penetrance RB is dominated by
nontruncating mutations [8,9,11,12]. Functionally, the RB1
mutations causing low-penetrance RB were shown either to
reduce the level of expression of normal RB1 protein or
produce a mutant RB1 protein that is only partially inactivated
[8,9]. However, recent insights strongly call into question this
assumption with the report of a chain-terminating mutation in
RB1 exon 1 in a large low-penetrance family with unilateral
RB and retinoma [13].
In this report, we correlate the clinical features of 17
retinoma patients to their underlying RB1 germline mutations.
Results are discussed in light of the recent advances regarding
the molecular basis of RB oncogenesis.
METHODS
The study was conducted in accordance to the tenets of the
Declaration of Helsinki. Out of more than 500 patients with
RB and their first-degree relatives treated between 1964 and
2008, we selected patients who had retinoma and a positive
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family history of RB or patients who had retinoma in one eye
and either RB or retinoma in the other eye. Patients were
referred to us either from university eye clinics and private
Swiss practitioners or from neighboring European countries.
All patients were examined and treated at the Retinoblastoma
Clinic of the Jules-Gonin Eye Hospital, Lausanne,
Switzerland. All patients and their first-degree relatives
underwent full ophthalmic examination and were documented
by fundus photographs and ultrasonography. Fluorescein and
indocyanine angiography was performed in selected patients.
Previously described diagnostic criteria for retinoma and
phthisis were used to identify the retinoma subpopulation
TABLE 1. PRIMERS AND PCR CONDITIONS.
Region Primer                       Sequence 5′-3′
Amplicon                            Annealing
     [bp]                                      [°C]
promoter PromF CTGGACCCACGCCAGGTTTC 340 61
PromR GTTTTGGGCGGCATGACGCCTT
RB exon 1 1F CCGGTTTTTCTCAGGGGACGTTG 340 56.4
1R TTGGCCCCGCCCTACGCACAC
RB exon 2 2F CTATTGAAACAAGTATGTACTG 331 54.3
2R GGGTAATGGAATTATTATTAGC
RB exon 3 3F CAGTTTTAACATAGTATCCAG 281 52.8
3R AGCATTTCTCACTAATTCAC
RB exon 4 4F GTAGTGATTTGATGTAGAGC 305 55
4R CCCAGAATCTAATTGTGAAC
RB exon 5 5F GCATGAGAAAACTACTATGAC 194 54.3
5R CTAACCCTAACTATCAAGATG
RB exon 6 6F CACCCAAAAGATATATCTGG 222 54.3
6R ATTTAGTCCAAAGGAATGCC
RB exon 7 7F CCTGCGATTTTCTCTCATAC 256 55
7R ATGTTTGGTACCCACTAGAC
RB exon 8 8F AGTAGTAGAATGTTACCAAG 380 50.8
8R TACTGCAAAAGAGTTAGCAC
RB exon 9 9F TGCATTGTTCAAGAGTCAAG 222 56
9R AGTTAGACAATTATCCTCCC
RB exon 10 10F TCTTTAATGAAATCTGTGCC 291 56
10R GATATCTAAAGGTCACTAAG
RB exon 11 11F GAGACAACAGAAGCATTATAC 245 54.2
11R CGTGAACAAATCTGAAACAC
RB exon 12 12F GGCAGTGTATTTGAAGATAC 310 52.5
12R AACTACATGTTAGATAGGAG
RB exon 13 13F CTTATGTTCAGTAGTTGTGG 342 54.3
13R TATACGAACTGGAAAGATGC
RB exon 14 14F GTGATTTTCTAAAATAGCAGG 212 58.9
14R TGCCTTGACCTCCTGATCTG
RB exon 15+16 15/16F CAATGCTGACACAAATAAGG 366 55
15/16R AGCATTCCTTCTCCTTAACC
RB exon 17 17F AAAAATACCTAGCTCAAGGG 339 56
17R TGTTAAGAAACACCTCTCAC
RB exon 18 18F TGTACCTGGGAAAATTATGC 340 56.4
18R CTTTATTTGGGTCATGTACC
RB exon 19 19F ATAATCTGTGATTCTTAGCC 273 56
19R AAGAAACATGATTTGAACCC
RB exon 20 20F AAAGAGTGGTAGAAAAGAGG 335 56.4
20R CAGTTAACAAGTAAGTAGGG
RB exon 21 21F AAACCTTTCTTTTTTGAGGC 328 54
21R TACATAATAAGGTCAGACAG
RB exon 22 22F TAATATGTGCTTCTTACCAGTC 313 56
22R TTTAATGTTTTGGTGGACCC
RB exon 23 23F ATCTAATGTAATGGGTCCAC 287 54.2
23R CTTGGATCAAAATAATCCCC
RB exon 24 24F GAATATAGTTTGTCAGTGGTTC 273 52 53
24R GTGTTTGAATAACTGCATTTGG
RB exon 25 25F GGTTGCTAACTATGAAACAC 297 54.2 55
25R AGAAATTGGTATAAGCCAGG
RB exon 26 26F AGTAAGTCATCGAAAGCATC 209 52.8
26R AACGAAAAGACTTCTTGCAG
RB exon 27 27F CGCCATCAGTTTGACATGAG 237 54.2
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[1]. Eight patients for whom DNA was not available were
excluded from this study. Informed consent was obtained
from all patients or parents to draw blood and perform genetic
analysis. A total of 22 patients were selected and screened for
RB1 mutations. Charts were reviewed for specific clinical
features such as age at diagnosis, tumor type (RB/retinoma),
and number of tumor foci per eye. The number of RB foci
could not be determined in all cases except one, which had a
diffuse form of RB, because patients had been enucleated
elsewhere in their childhood and we did not have access to the
clinical or histopathological data. DER was calculated for
each family.
DNA was extracted from blood leukocytes and used for
PCR amplification. Genetic analysis was performed at the
Institut de Recherche en Ophtalmologie. Previously described
denaturing high-performance liquid chromatography
(DHPLC) [14] and sequencing were used. Amplification was
performed in a thermal cycler (GeneAmp 9700; Applied
Biosystems, Foster City, CA), in a total volume of 30 μl. Each
polymerase chain reaction (PCR) contained 100 ng genomic
DNA, 0.9 nanomoles of each primer, and 15 μl master mix 2X
(Qiagen, Hombrechtikon, Switzerland), with or without
betaine. Reactions were subjected to 35 cycles of 94 °C for 1
min, annealing at the specific temperature for 1 min, 72 °C for
1 min, and a final extension step at 72 °C for 10 min. Sequence
of primers and PCR conditions are presented in Table 1. After
PCR amplification, products were screened for mutations
using DHPLC on a WAVE system (Transgenomic, Crewe,
Cheshire, UK). Buffer contained 0.1 M triethylammonium
acetate (TEAA, Transgenomic). Buffer B contained 0.1 M
TEAA and 25% acetonitrile HPLC grade (Sigma-Aldrich,
Suffolk, UK). The flow rate was set at 1.5 ml/min and the
Buffer B gradient increased by 5% per minute for 2 min. The
optimum temperature was determined by the Wavemaker
software (Transgenomic) for each DNA fragment, and a time
shift was applied as needed [11]. When multiple melting
domains were established, each domain was analyzed at the
appropriate temperature. Initial Buffer B concentrations and
temperatures for each fragment are listed Table 1. PCR
fragments displaying DHPLC abnormal retention times were
further sequenced on both strands using ABI Dye Terminator,
version 1 or 3, in a final reaction volume of 10 μl, and
electrophoresed on a 3130XL ABI genetic analyzer (Applied
Biosystems). Sequences were aligned using the
Chromasversion 2.23 (Technelysium, Tewantin, Australia).
Screening for large deletions was performed by haplotype
analysis using RB1 flanking microsatellites D13S161,
S13S164, D13S153, D13S1307, and D13S273. One primer
was fluorescently labeled, and the product was separated on
an automated sequencer (ABI XL3100; Applied Biosystems).
RESULTS
Out of the 22 selected patients, 18 were familial from 11
families and four were sporadic. Out of the 18 familial cases,
we identified mutations in 15 cases, which were from nine
families, and we found mutations in two of the four sporadic
cases. Thus, we had 11 index cases in total with proven
germline mutations. Patient clinical features and mutation
descriptions are detailed in Table 2.
Median age at diagnosis was 30.8 years (range 8 months
to 62 years). Mean number of retinoma foci per eye was
1.88±1.5. Four of the identified mutations were not previously
reported (Table 2).
DISCUSSION
We studied 22 patients with retinomas and detected RB1
mutations in 17 (15 familial cases and in 2 sporadic) of them.
The 15 familial cases belonged to nine families that were not
low-penetrance ones (DER 1.1 to 2). In accordance with the
results of Sanchez-Sanchez et al. [13], the observation of
retinoma with predisposing nonsense germline mutation does
not support the hypothesis that truncating mutations do not
cause retinoma. Indeed, truncating mutations were found in
70% of retinoma patients in this study. We tried to determine
if a certain type of mutation could cause higher expressivity
leading to multiple tumor foci in each eye, but there was no
correlation between the type of mutation and the number of
tumor foci per eye (RB or retinoma). In our cohort most
mutations were either nonsense mutations, duplication or
deletions. Although we did not analyze the consequences of
the observed mutations at the RNA level, we can reasonably
assume that they represent truncating mutations. The case of
the two remaining mutations, R46K and E737D, is more
complicated. They could represent true missense mutations or
could affect splicing of the nearby intron. Their pathogenicity
is not questionable, as they have been reported to cause
bilateral RB [15]. We have previously described the
L42RfsX25 mutation located in exon 1 [11]. Alternative
translation might be the mechanism by which different levels
of expressivity are present within this family (F1, Figure 1).
In contrast with the family studied by Sanchez-Sanchez
[13], all nine families in our series had DER above 1.0,
suggesting absence of low-penetrance. That the mean number
of retinoma foci per eye was 1.88 indicates a relatively high
level of expressivity. Furthermore, we observed that the same
truncating mutation located in exon 11 and 23 led in Family
4 and 9 respectively (Figure 2) to highly heterogeneous
expressivity ranging from the most severe bilateral RB to
bilateral retinoma. This occurrence has not previously been
described in association with severe truncating mutations.
Notably, that the predisposing mutation was located at the
carboxyl-terminus of the RB1 gene (Family 9) suggests that
another mechanism than alternative translation initiation may
be involved. Unfortunately, in none of the families with
truncating mutations could we perform functional analysis to
determine the level of activity of the protein products. To the
best of our knowledge, this is the first report focusing on
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germline mutations in retinoma cases. That we did not detect
mutations in two families and two sporadic cases might be due
to the technology applied that would not detect copy number
changes of exons or most mosaicism. However, the 73% of
RB1 mutations (11 mutations found in 15 participants who had
bilateral or familial RB) detected by the technologies applied
suggests that the spectrum of mutations associated with
retinoma is the same as for RB. Further work is needed in
collaboration with other laboratories to use other mutation
screening technologies to identify mutations in the remaining
cases and to analyze the consequences of the observed
mutations at the RNA level. This is beyond the intended scope
of the present work. Although no statistical analysis was
possible in this study, in accordance with other published
series [4,16], we propose that retinoma should not be
considered a form of attenuated expressivity [17-22], but
rather the result of variable expressivity occurring in a
penetrance independent manner.
Gallie et al. [23] have hypothesized that the stage of cell
maturation at which the second RB1 mutation occurs is
determinant for the phenotype expression. We observed one
case in this series, Patient 11, who underwent malignant
transformation of his retinoma, at an adult age. This
observation has been previously reported by others [2,4,23,
24] and may support the stage of cell maturation theory with
the understanding that a primitive cell could have remained
latent for many years before becoming activated in the eye of
an adult [23]. Another mechanism has been proposed to
understand attenuated expressivity represented in this study
by retinoma. Recent histopathological analysis of eyes
enucleated for RB showed retinoma tumors adjacent to both
normal retina and RB tumors in up to 15.6% (20/128),
suggesting clonal progression from a normal cell to a benign
one and finally to a malignant cell [16]. Other researchers have
[16] reported molecular evidence of this clonal progression,
showing that retinomas and RBs were homozygous null for
RB1, could share the same mutation of whatever class,
including stop codon, and that retinomas expressed
senescence proteins maintaining them in an arrested state.
Retinomas displayed genomic changes such as gain of
oncogenes and genomic instability to a lesser degree than RB,
which is thought to develop by escaping the senescence state
of retinomas [16]. This hypothesis of increasing genomic
instability for the development of RB is in accordance with
the results we present. Unfortunately, we were not able to
study the type of the second-hit mutation, which might be
determinant, too, in cell destiny.
Conclusions: RB development understanding remains a
challenging but mandatory task due to the life-threatening
complications it can induce. Its causative gene, RB1, has
opened the way to the two-hit theory [6], the limitations of
which have been highlighted by the study of retinoma, a
benign tumor. For a long time, retinoma has been considered
to be part of the low-expressivity as well as low-penetrance
Figure 1. Pedigree of Family 1 and
Family 2. Pedigree of the Family 1 in
which the L42RfsX25 truncating
mutation segregates is presented.
Alternative translation might be the
mechanism by which different level of
expressivity are present within this
family ranging from bilateral RB to
unilateral retinomas. In Family 2 which
includes an unaffected R46K mutation
carrier, the level of expressivity is even
lower. This mutation has been
previously reported. Solid black
symbols represent bilateral
retinoblastoma (RB). Half black
symbols represent unilateral RB. Solid
gray symbols represent bilateral
retinoma. Half gray symbols represent
unilateral retinoma. The slashed symbol
represents deceased individual, and
symbol with a black dot represents an
unaffected mutation carrier.
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presentation and thought to be caused by less severe inherited
mutations. We have shown in this series that even severe
inherited mutations segregating in families with bilateral RB
patients can also cause retinoma. Recently, it has been shown
that RB emerges from retinoma after accumulation of
genomic changes, whereas retinoma develops after
homogeneous loss of RB1 [16]. Thus, what we used to
consider as low or attenuated expressivity should be revisited
as a step in the cell pathway to malignant tumor development.
Genetic counseling, treatment, and follow-up
recommendations may highly be influenced by such advances
in RB and retinoma development understanding.
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